News and Press Releases
Press releases
Theralase Manufactures First Pre-Commercial Batch of Lead Anti-Cancer Drug
Press ReleaseToronto, Ontario – April 9, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has successfully manufactured the first pre-commercial batch of its lead anti-c...
Theralase Holds pre-CTA Meeting with Health Canada
Press ReleaseToronto, Ontario – April 2, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it recently held a pre “Clinical Trial Application” (“CTA”) consultation m...
Theralase Partners with CiToxLAB for Toxicology
Press ReleaseToronto, Ontario – March 23, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has partnered with CiToxLAB Safety and Health Research Laboratories (“CiToxL...
Theralase Confirms Strategic Initiatives
Press ReleaseToronto, Ontario – March 11, 2015, Theralase Technologies Inc. (“Theralase” or the “Company”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today confirmation of its strategic initiatives for 2015. On March 3, 2015, Theralase closed...
Theralase Announces Completion of Public Offering of Units
Press ReleaseToronto, Ontario – March 3, 2015, Theralase Technologies Inc. (“Theralase” or the “Corporation”) (TSXV:TLT) (OTC Pink®: TLTFF) is pleased to announce that it has closed its previously announced public offering (the “Offer...
Theralase Identifies Potential Mechanism of How Lead Anti-Cancer Drug Works to Destroy Cancer and Discovers New Application to Detect Cancer Cells
Press ReleaseToronto, Ontario – February 23, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has identified a potential mechanism of how its lead anti-cancer drug works to destroy cancer ce...
Theralase’s Lead Anti-Cancer Drug Has Significantly Less Skin Toxicity than FDA Approved Drug
Press ReleaseToronto, Ontario – February 13, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®), a developer of advanced Photo Dynamic Therapy (“PDT”), for serious and life-threatening diseases, announced toda...
Theralase Ranked in 2015 Toronto Stock Exchange Venture 50®
Press ReleaseToronto, Ontario – February 11, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has been ranked in the Toronto Stock Exchange Venture (“TSXV”) 50®. Every year, the TSX Ven...
Theralase Files Health Canada Approval for Next Generation Therapeutic Laser
Press ReleaseToronto, Ontario – February 9, 2015, Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink®) announced today that it has successfully completed the design of the next generation therapeutic laser, the TLC-2000, and...
Theralase Anti-Cancer Technology Research Accepted for Peer Reviewed Publication
Press ReleaseToronto, Ontario, February 3, 2015 /Theralase Technologies Inc. (“Theralase”) (TLT:TSXV) (TLTFF: OTC Pink(R)), a developer of advanced Photo Dynamic Therapy (“PDT“), for serious and life-threatening diseases, announced today that resea...
in the news
July 6, 2023
Vrian Crombie Radio Interview with Roger DuMoulin-White - President and Chief Executive Officer
may 18, 2023
Promising Developments in the Theralase® Project of Intravesical Photodynamic Therapy for BCG Unresponsive Bladder Cancer - Girish Kulkarni
Let's Stay in Touch
Sign up to our newsletter to stay informed on news and updates from Theralase Technologies Inc.
